ReviewOncoTargets and therapy2016
Hürthle cell carcinoma: current perspectives.
Review in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- ESR Essentials: thyroid imaging-practice recommendations by the European Society of Head and Neck Radiology.European radiology · 2026Guideline
- Hürthle Cell Carcinoma of the Thyroid Gland: Systematic Review and Meta-analysis.Advances in therapy · 2021Pooled it
- Conventional sonographic phenotype of thyroid oncocytic neoplasms: a pathology-confirmed comparative study.Journal of ultrasound · 2026Article
- Redifferentiation-enabled TSHRCART cells overcome antigen loss in aggressive thyroid cancers.Molecular cancer · 2026Article
- Differentiating oncocytic carcinoma from oncocytic adenoma: a comprehensive evaluation of preoperative characteristics and diagnostic approaches in a retrospective cohort study.Annals of surgical treatment and research · 2025Article
- Metastasis of oncocytic thyroid carcinoma in the mandibular condyle: An exceptional localization.Journal of clinical and experimental dentistry · 2025Article
- The preliminary multicenter retrospective study on the efficacy and safety of thermal ablation for follicular thyroid neoplasms ≤ 3 cm.Discover oncology · 2025Article
- Thyroid Cancer Prevalence, Risk Exposure, and Clinical Features Among Transgender Female Veterans.Journal of the Endocrine Society · 2024Article
- Megaprosthesis for a Rare Case of Bone Metastasis of Thyroid Carcinoma: Case Management and Surgical Approach.Cureus · 2024Article
- Somatostatin Receptor Type 2 and Thyroid-Stimulating Hormone Receptor Expression in Oncocytic Thyroid Neoplasms: Implications for Prognosis and Treatment.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2023Article
- Thyroid collision tumour with pulmonary metastases treated effectively with nedaplatin and paclitaxel chemotherapy: A case report.The Journal of international medical research · 2023Article
- Surgical management of metastatic Hürthle cell carcinoma to the skull base, cortex, and spine: illustrative case.Journal of neurosurgery. Case lessons · 2023Article
- Multi-Omics and Management of Follicular Carcinoma of the Thyroid.Biomedicines · 2023Review
- Lenvatinib as a Promising Treatment Option for Unresectable Hürthle Cell Carcinoma: A Case Report.Cureus · 2023Article
- Article
- Development and validation of a prognostic nomogram for Hürthle cell thyroid carcinoma: a SEER-based study.Gland surgery · 2022Article
- Follicular and Hurthle Cell Carcinoma: Comparison of Clinicopathological Features and Clinical Outcomes.Thyroid : official journal of the American Thyroid Association · 2022Article
- Thyroid collision tumor containing oncocytic carcinoma, classical and hobnail variants of papillary carcinoma and areas of poorly differentiated carcinoma.Archives of endocrinology and metabolism · 2021Article
- Synchronous occurrence of Hurthle cell carcinoma with Hodgkin's lymphoma; the first reported case with literature review.Annals of medicine and surgery (2012) · 2021Article
- Site-Specific Metastasis and Survival in Papillary Thyroid Cancer: The Importance of Brain and Multi-Organ Disease.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hürthle cell carcinoma (HCC) can present either as a minimally invasive or as a widely invasive tumor. HCC generally has a more aggressive clinical behavior compared with the other differentiated thyroid cancers, and it is associated with a higher rate of distant metastases. Minimally invasive HCC demonstrates much less aggressive behavior; lesions <4 cm can be treated with thyroid lobectomy alone, and without radioactive iodine (RAI). HCC has been observed to be less iodine-avid compared with other differentiated thyroid cancers; however, recent data have demonstrated improved survival with RAI use in patients with HCC >2 cm and those with nodal and distant metastases. Patients with localized iodine-resistant disease who are not candidates for a wait-and-watch approach can be treated with localized therapies. Systemic therapy is reserved for patients with progressive, widely metastatic HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.